Warning letter
Rainbow Gold Products Inc: warning letter of May 4, 2017
FDA warning letter 508837 · New Orleans District Office
Key facts
| Reference number | 508837 |
|---|---|
| Company | Rainbow Gold Products Inc |
| Subject | Unapproved New Drugs/Misbranded |
| Issue date | May 4, 2017 |
| Posted date | May 9, 2017 |
| Issuing office | New Orleans District Office |
| Product type | Drugs |
| CFR sections cited | 201.5, 207.57(b)(1)(ii) |
| Inspection city | Sardis City |
| Inspection ZIP | 35956 |
| Inspection start date | Aug 8, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: